Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Inclusion Criteria: * Histologically confirmed invasive adenocarcinoma of the breast or inflammatory breast cancer, with an interval between definitive breast surgery and study registration of \<60 days. * Definitive surgical treatment must be either mastectomy or breast-conserving therapy with axillary lymph node dissection for operable breast cancer (pT1 4 \[including inflammatory breast cancer\], pN0 3, and M0). Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in situ (DCIS). Lobular carcinoma in-situ does not count as a positive margin. * Patients with ≥1 axillary lymph node containing metastatic adenocarcinoma measuring \>0.2 mm, OR lymph node-negative patients with high-risk features * Patients with HER2/neu positive or negative tumors (HER2 positivity must be documented by FISH positivity or IHC 3+). * Patients who are to receive trastuzumab must have normal cardiac function (MUGA \[cardiac ejection fraction \>50%, or greater than or equal to the institutional lower limit of normal\], or echocardiogram \[ECHO\] within institutional normal limits). * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2. * Patients who are either chemotherapy naïve, or who have received prior chemotherapy \>5 years ago. * Patients with previous invasive cancers (including breast cancer) eligible only if treated \>5 years prior to entering this study, and show no evidence of recurrent disease. * Adequate bone marrow function * Adequate liver function, * Adequate renal function, * Patients of childbearing potential must use an effective method of contraception that is acceptable to their study physician from the time of signing informed consent until at least 3 months after the last dose of protocol treatment, and must have a negative pre study serum pregnancy test. * Pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria. * MammoSite® brachytherapy radiation accepted when performed immediately following surgery and prior to receiving chemotherapy. * Patients with bilateral, synchronous breast cancer, provided that one primary tumor meets the inclusion criteria. Exclusion Criteria: * Patients who are pregnant or breastfeeding. * M1 metastatic disease. * Patients requiring neoadjuvant chemotherapy. * Life expectancy of greater than 6 months. * History of cardiac disease, with a New York Heart Association (NYHA) Class II or greater CHF * Myocardial infarction (MI) or unstable angina in the past 12 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment, any history of stroke or transient ischemic attack at any time, clinically significant peripheral vascular disease, or evidence of a bleeding diathesis or coagulopathy. * Any investigational agent within 30 days of receiving the first dose of study drug. * Treatment with prior trastuzumab or bevacizumab therapy. * Concurrent treatment with any other anti-cancer therapy is not permitted. * History of significant psychiatric disorders. * History of active, uncontrolled infection. * A serious, non-healing wound, ulcer, or bone fracture. * Any other diseases, metabolic dysfunction, findings from a physical examination, or clinical laboratory test results that give reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results or that renders the patient at high risk from treatment complications.